Scholarlink

The JAK signaling pathway has a critical role in the pathogenesis of various chronic inflammatory diseases, such as atopic dermatitis. Abrocitinib, an oral selective Janus kinase 1 inhibitor, holds promise as an effective therapeutic approach for the treatment of moderate-to-severe atopic dermatitis. This section will comprehensively explore abrocitinib, covering its chemical structure, pharmacokinetic and pharmacodynamic characteristics, and the safety considerations linked to its utilization.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Selective JAK Inhibitor: Abrocitinib (JAK1-Selective)

  • 章节

  • 发表日期：

    2025年

查看全文
  • Ümmühan Şeker,
  • Kenan Aydoğan

摘要

The JAK signaling pathway has a critical role in the pathogenesis of various chronic inflammatory diseases, such as atopic dermatitis. Abrocitinib, an oral selective Janus kinase 1 inhibitor, holds promise as an effective therapeutic approach for the treatment of moderate-to-severe atopic dermatitis. This section will comprehensively explore abrocitinib, covering its chemical structure, pharmacokinetic and pharmacodynamic characteristics, and the safety considerations linked to its utilization.